2-Star Stocks Poised to Plunge: Geron?

Based on the aggregated intelligence of 180,000-plus investors participating in Motley Fool CAPS, the Fool's free investing community, biopharmaceutical company Geron (Nasdaq: GERN  ) has received a distressing two-star ranking.

With that in mind, let's take a closer look at Geron and see what CAPS investors are saying about the stock right now.

Geron facts

Headquarters (founded) Menlo Park, Calif. (1990)
Market Cap $217.9 million
Industry Biotechnology
Trailing-12-Month Revenue $1.9 million
Management CEO Dr. John Scarlett (since September 2011)
CFO Graham Cooper (since January 2012)
Return on Equity (average, past 3 years) (55.1%)
Cash/Debt $118.2 million / $0
Competitors Bristol-Myers Squibb
GlaxoSmithKline
Novartis

Sources: S&P Capital IQ and Motley Fool CAPS.

On CAPS, 17% of the 107 All-Star members who have rated Geron believe the stock will underperform the S&P 500 going forward.

Just yesterday, one of those Fools, zzlangerhans, nicely summed up the bear case for our community:

Can't say I'm feeling the Geron rebound after the crushing failure of imetelstat in breast cancer and lung cancer. After all, this is the drug that Geron gave up stem cell research to focus on. A buck seventy share price may seem low, but that translates into a market cap of 225M due to years of unchecked dilution. The company only has a year and a half of cash at the current burn rate and the next catalyst will be topline phase II data for, you guessed it, imetelstat in hematologic malignancies before the end of 2012. Geron's only other compound in clinical trials is GRN1005, a relatively inexpensive acquisition in phase II for brain tumors. Another very tough indication and not a lot of reason to expect success.

Geron could certainly provide upside surprises but there's no reason for a run-up going into any of this data given the already-generous market cap. Given what's happened recently to Geron and now ArQule, I really have to question the wisdom of long positions in developmental oncology companies with unpredictable interim data catalysts.

If you want market-topping returns, you need to protect your portfolio from any undue risk. Luckily, we've found another growth play we are incredibly excited about -- excited enough to dub it "The Only Stock You Need to Profit from the NEW Technology Revolution." We have compiled a special free report for investors to uncover this stock today. The report is 100% free, but it won't be here forever, so click here to access it now.

Want to see how well (or not so well) the stocks in this series are performing? Follow the TrackPoisedTo CAPS account.

Fool contributor Brian Pacampara owns no position in any of the companies mentioned. Try any of our Foolish newsletter services free for 30 days.

We Fools may not all hold the same opinions, but we all believe that considering a diverse range of insights makes us better investors. The Fool's disclosure policy always gets a perfect score.


Read/Post Comments (2) | Recommend This Article (2)

Comments from our Foolish Readers

Help us keep this a respectfully Foolish area! This is a place for our readers to discuss, debate, and learn more about the Foolish investing topic you read about above. Help us keep it clean and safe. If you believe a comment is abusive or otherwise violates our Fool's Rules, please report it via the Report this Comment Report this Comment icon found on every comment.

Add your comment.

Sponsored Links

Leaked: Apple's Next Smart Device
(Warning, it may shock you)
The secret is out... experts are predicting 458 million of these types of devices will be sold per year. 1 hyper-growth company stands to rake in maximum profit - and it's NOT Apple. Show me Apple's new smart gizmo!

DocumentId: 2041914, ~/Articles/ArticleHandler.aspx, 10/23/2014 10:56:03 AM

Report This Comment

Use this area to report a comment that you believe is in violation of the community guidelines. Our team will review the entry and take any appropriate action.

Sending report...


Advertisement